SCHEMBL1041069

SCHEMBL1041069

CC=CCCCC(=O)NCC

nearest known ligand 0.66

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
FAAH O00519 4/20 0.55
CNR1 P21554 6/20 0.50
ALDH1A1 P00352 3/20 0.49
MEN1 O00255 2/20 0.49
BLM P54132 2/20 0.49
KMT2A Q03164 2/20 0.49
MAPT P10636 2/20 0.49
HPGD P15428 2/20 0.49
TDP1 Q9NUW8 2/20 0.49
KDM4E B2RXH2 1/20 0.49
USP2 O75604 1/20 0.49
POLB P06746 1/20 0.49
CYP3A4 P08684 1/20 0.49
ALOX15 P16050 1/20 0.49
APEX1 P27695 1/20 0.49
RECQL P46063 1/20 0.49
PMP22 Q01453 1/20 0.49
GPR18 Q14330 1/20 0.49
HSD17B10 Q99714 1/20 0.49
SLC6A5 Q9Y345 1/20 0.49

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL1584861 1.00 FAAH (0.55) FAAHCNR1ALDH1A1MEN1BLM
SCHEMBL10112508 1.00 FAAH (0.55) FAAHCNR1ALDH1A1MEN1BLM
SCHEMBL15468144 0.92 FAAH (0.62) FAAHCNR1ALDH1A1MEN1BLM
SCHEMBL29508694 0.89 FAAH (0.48) FAAHCNR1ALDH1A1MEN1BLM
SCHEMBL12464505 0.86 CNR1 (0.65) FAAHCNR1ALDH1A1MEN1BLM
SCHEMBL29382683 0.82 FAAH (0.50) FAAHCNR1ALDH1A1MEN1BLM
SCHEMBL22618724 0.82 TRPV1 (0.51) FAAHCNR1ALDH1A1MEN1BLM
SCHEMBL19557781 0.81 CNR1 (0.73) FAAHCNR1ALDH1A1MEN1BLM
SCHEMBL31540133 0.80 FAAH (0.68) FAAHCNR1ALDH1A1MEN1BLM
SCHEMBL23352597 0.80 EPHX2 (0.65) CNR1MEN1KMT2AMAPTSLC6A5

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 13 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
CN-114174261-B Method for preparing nitric oxide donor type prostaglandin analogue 尼科斯股份有限公司 2025-02-07 CN disclosed
WO-2024092085-A1 AQUEOUS PHARMACEUTICAL COMPOSITIONS OF PROSTAGLANDINS FAMYGEN LIFE SCIENCES, INC. (US) 2024-05-02 WO disclosed
EP-4288413-A1 PROCESS FOR THE PREPARATION OF A NITRIC OXIDE DONATING PROSTAGLANDIN ANALOGUE Nicox S.A. (FR) 2023-12-13 EP disclosed
CN-116829537-A Process for preparing prostaglandin analogues supplied with nitric oxide 尼科斯股份有限公司 2023-09-29 CN disclosed
CN-111757868-B Nitric oxide donating prostaglandin analogs 尼科斯股份有限公司 2023-03-14 CN disclosed
WO-2022167070-A1 PROCESS FOR THE PREPARATION OF A NITRIC OXIDE DONATING PROSTAGLANDIN ANALOGUE NICOX S.A. (FR) 2022-08-11 WO disclosed
CN-114174261-A Method for preparing nitric oxide donor type prostaglandin analogue 尼科斯股份有限公司 2022-03-11 CN disclosed
US-20200123322-A1 BIODEGRADABLE DRUG-POLYMER CONJUGATE POLYACTIVA PTY LTD (AU) 2020-04-23 US disclosed
EP-2864308-A1 COMPOUND AND METHOD University Of Bristol (GB) 2015-04-29 EP disclosed
WO-2013186550-A1 COMPOUND AND METHOD UNIVERSITY OF BRISTOL (GB) 2013-12-19 WO disclosed
EP-2488508-A1 PROCESS FOR THE PREPARATION OF F-SERIES PROSTAGLANDINS Cayman Chemical Company, Incorporated (US) 2012-08-22 EP disclosed
WO-2011046569-A1 PROCESS FOR THE PREPARATION OF F-SERIES PROSTAGLANDINS CAYMAN CHEMICAL COMPANY (US) 2011-04-21 WO disclosed
EP-2274279-A1 NITRIC OXIDE DONATING PROSTAMIDES Nicox S.A. (FR) 2011-01-19 EP disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20200123322-A1 BIODEGRADABLE DRUG-POLYMER CONJUGATE ADRB3, PTGER3, CHRNE FAAH 821/4885CNR1 210/4885ALDH1A1 1039/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.